WuXi Biologics (Cayman) Inc. (2269.HK)
| Previous Close | 17.900 |
| Open | 18.400 |
| Bid | 18.020 x 0 |
| Ask | 18.040 x 0 |
| Day's Range | 17.780 - 18.800 |
| 52 Week Range | 10.140 - 52.450 |
| Volume | |
| Avg. Volume | 73,136,911 |
| Market Cap | 73.958B |
| Beta (5Y Monthly) | 0.63 |
| PE Ratio (TTM) | 27.30 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire
WuXi Biologics Included in Hang Seng ESG 50 Index
WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that it has been included in the Hang Seng ESG 50 Index, making it the only pharmaceutical company selected this year. The Index became effective September 9, following the Hang Seng Indexes review results announcement in August.
- PR Newswire
WuXi Biologics Successfully Completes First Scale-Up of High-Productivity Bioprocessing Platform WuXiUI™ in 2,000L GMP Manufacturing
WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that it has successfully accomplished 2,000L drug substance (DS) GMP manufacturing by utilizing its proprietary ultra-intensified fed-batch bioprocessing platform WuXiUI™. The platform achieved a titer of 18 g/L, a 4-fold increase compared to conventional fed-batch process, demonstrating the high efficiency of WuXiUI™ in improving productivity.
- PR Newswire
WuXi Biologics Reports Solid 2024 Interim Results
WuXi Biologics (Cayman) Inc. ("WuXi Biologics" or "the Group", stock code: 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) service company offering end-to-end solutions for biologics discovery, development and manufacturing, is pleased to announce its unaudited interim results for the first half of 2024 ("Reporting Period").
